title: Growth hormone as a new treatment modality for short children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure.
abstract: Recombinant human growth hormone (rhGH) has become a new treatment modality for short children with chronic renal failure (CRF) and after renal transplantation. The rationale for high-dose rhGH treatment is the insensitivity of the uremic organism to GH. As the insensitivity to GH is expressed more in end-stage renal failure than in earlier stages of CRF, patients on dialysis respond less to rhGH. In transplanted children, rhGH can counterbalance the growth-depressing effects of corticosteroids. In prepubertal children, rhGH improves the height standard deviation score by a mean of +2 within 5 years. The effect of rhGH treatment on final height remains to be studied.
authors.affiliation: Division of Pediatric Nephrology, University Children's Hospital of Heidelberg, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Mehls
authors.forename: D
authors.initials: D
authors.lastname: Haffner
authors.forename: E
authors.initials: E
authors.lastname: Wühl
authors.forename: B
authors.initials: B
authors.lastname: Tönshoff
authors.forename: F
authors.initials: F
authors.lastname: Schaefer
authors.forename: U
authors.initials: U
authors.lastname: Heinrich
mesh_terms: D002648:Child; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology*; D019382:Human Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D016030:Kidney Transplantation; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
chemical_list: D011994:Recombinant Proteins; D019382:Human Growth Hormone